Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Anti-AI Investing: The HALO Moat
08:00am, Sunday, 31'st May 2026
I focus on HALO investing: Heavy Assets, Low Obsolescence - owning irreplaceable physical assets with durable moats against technological disruption. Top recommendations include American Tower, Brookf
Implied Volatility Surging for Halozyme Therapeutics Stock Options
10:31am, Tuesday, 26'th May 2026
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
Halozyme Therapeutics: Royalty King
10:33pm, Tuesday, 19'th May 2026
Halozyme Therapeutics is delivering strong shareholder value, driven by robust royalty growth and disciplined capital allocation. HALO posted a double beat on Q1 2026 earnings, reaffirmed 2026–2028
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD Acquisition gives Nexalin control of AI-int
One of the market's hottest stock themes is buying everything AI can't replace
10:21am, Sunday, 17'th May 2026
Josh Brown, co-founder and CEO of Ritholtz Wealth Management, coined the term HALO as a way to identify companies immune to AI disruption. Many HALO stocks are outperforming this year, such as FedEx,
Roundhill launches "HALO" ETF
04:51pm, Thursday, 14'th May 2026
Dave Mazza, CEO of Roundhill Investments, joins CNBC's "Halftime Report" to highlight the launch of their new "HALO" ETF coined by our very own Josh Brown. It stands for "Heavy Assets, Low Obsolescenc
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
12:51pm, Tuesday, 12'th May 2026
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
10:50pm, Monday, 11'th May 2026
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics Q1 Earnings Call Highlights
08:09pm, Monday, 11'th May 2026
Halozyme Therapeutics NASDAQ: HALO reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say
06:31pm, Monday, 11'th May 2026
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key met
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
06:16pm, Monday, 11'th May 2026
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.11 per share a year ago.
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
04:01pm, Monday, 11'th May 2026
Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026 Total Revenue Increased 42% YOY to $377 million Royalty Revenue Increased 43% YOY to $241 millio
Meet The Nvidia HALO Trade: 6 Stocks That May Rise Every Time Jensen Huang Scales AI
12:54pm, Thursday, 07'th May 2026
Nvidia Corp (NASDAQ:NVDA) may still be the center of the AI trade. But Wall Street is increasingly starting to chase the layer underneath it.
Marks first ENHANZE ® agreement to include ADC targets Collaboration also includes option for additional future targets First clinical trial projected to initiate in 2026 SAN DIEGO, May 7, 2026 /PRNe
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:15am, Wednesday, 06'th May 2026
Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared
